跳至主要内容
临床试验/ACTRN12612000375853
ACTRN12612000375853已完成不适用

A Single Dose Clinical Trial to Study the Safety, Tolerability, and Pharmacokinetics of Intravenous MK-8226 in Healthy Subjects

Merck Sharp and Dohme Corp, a subsidiary of Merck & Co., Inc.0 个研究点目标入组 42 人开始时间: 2012年4月2日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
42

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment

入排标准

年龄范围
18 Years 至 50 Years(—)
性别
All

入选标准

  • Subject judged to be in good health based on medical history, physical examination, ECG, vital sign measurements and laboratory safety tests
  • -Non-smoker
  • -BMI <30kg/m2

排除标准

  • -Mentally or legally incapacitated or having significant emotional problems or has a history of clinically significant psychiatric disorder
  • -History of any clinically significant diseases/disorders
  • -Creatinine Clearance <80mL/min
  • -History of neoplastic disease
  • -Pregnant, breast feeding or expecting to conceive
  • -Major surgery or blood donation within 4 weeks
  • -Consumes excessive amounts of alcohol or caffeine
  • -History of significant allergies
  • -Regular/recreational drug user
  • -Participated in another clinical study within 4 weeks
  • -Positive to Hepatitis B, C or HIV
  • -Recent history of serious infection/infection requiring systemic antibiotics
  • -Received a live virus vaccine within 4 weeks.

研究者

发起方
Merck Sharp and Dohme Corp, a subsidiary of Merck & Co., Inc.

相似试验

A Single Dose Clinical Trial to Study the Safety,... | 临床试验